For research use only. Not for therapeutic Use.
Clavulanate Lithium（Cat No.:R023387）is a potent β-lactamase inhibitor commonly used in combination with β-lactam antibiotics to enhance their effectiveness against resistant bacteria. It works by irreversibly binding to β-lactamase enzymes, which typically degrade β-lactam antibiotics, thus protecting the antibiotic from enzymatic destruction. This combination therapy is vital for treating infections caused by β-lactamase-producing microorganisms. Clavulanate Lithium plays a crucial role in extending the spectrum of β-lactam antibiotics, providing an effective treatment option for various bacterial infections, particularly those resistant to standard therapy.
| Catalog Number | R023387 |
| CAS Number | 61177-44-4 |
| Synonyms | (2R,5R,Z)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate Lithium; |
| Molecular Formula | C8H8LiNO5 |
| Purity | ≥95% |
| Target | Beta-lactamase |
| Storage | -20°C |
| IUPAC Name | lithium;(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate |
| InChI | InChI=1S/C8H9NO5.Li/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4;/h1,6-7,10H,2-3H2,(H,12,13);/q;+1/p-1/b4-1-;/t6-,7-;/m1./s1 |
| InChIKey | JMRXTGCDVQLAFM-JSYANWSFSA-M |
| SMILES | [Li+].C1[C@@H]2N(C1=O)[C@H](/C(=C/CO)/O2)C(=O)[O-] |
| Reference | Pitout JD, Sanders CC, Sanders WE Jr. Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. Am J Med 1997; 103:51.<br/><br/>Wise, R., J. M. Andrews, and K. A. Bedford. /In Vitro Study of Clavulanic Acid in Combination with Penicillin, Amoxycillin, and Carbenicillin./ Antimicrobial Agents and Chemotherapy 13.3 (1978): 389-93. Ncbi.gov. Web. 2 Nov. 2012.</span></p> |
